Lumican与肿瘤治疗抵抗

doi:10.3760/cma.j.cn371439-20220621-00018

国际肿瘤学杂志 ›› 2023, Vol. 50 ›› Issue (2): 87-90.doi: 10.3760/cma.j.cn371439-20220621-00018

Lumican与肿瘤治疗抵抗

胡格¹, 夏凡¹, 吴雪芽¹, 王云², 徐秀理¹()

¹中国科学院合肥肿瘤医院综合四科，合肥 230000
²中国科学院合肥肿瘤医院胸部肿瘤中心，合肥 230000

收稿日期:2022-06-21 修回日期:2022-07-04 出版日期:2023-02-08 发布日期:2023-03-22
通讯作者: 徐秀理，Email：2394884805@qq.com
基金资助:
安徽省自然科学基金(AHWJ2021b087);中国科学院合肥肿瘤医院优秀医学青年人才计划(YQJH2021005)

Lumican and tumor therapy resistance

Hu Ge¹, Xia Fan¹, Wu Xueya¹, Wang Yun², Xu Xiuli¹()

¹Fourth Department of Comprehensive Medicine，Hefei Cancer Hospital，Chinese Academy of Sciences，Hefei 230000，China
²Thoracic Oncology Center，Hefei Cancer Hospital，Chinese Academy of Sciences，Hefei 230000，China

Received:2022-06-21 Revised:2022-07-04 Online:2023-02-08 Published:2023-03-22
Contact: Xu Xiuli，Email：2394884805@qq.com
Supported by:
Natural Science Foundation of Anhui Province of China(AHWJ2021b087);Outstanding Medical Young Talents Program of Hefei Cancer Hospital，Chinese Academy of Sciences(YQJH2021005)

摘要/Abstract

摘要：

Lumican是富含亮氨酸重复序列的小分子蛋白聚糖家族成员之一，参与肿瘤发生发展相关的细胞过程如上皮间质转化、细胞增殖、迁移、侵袭和黏附等。Lumican在不同肿瘤中的表达与肿瘤进展呈正相关或负相关，并可作为肿瘤预后及疗效评估参考。深入研究Lumican与肿瘤治疗抵抗的相关性及潜在机制可为临床治疗疗效预测提供新思路。

关键词: 肿瘤, Lumican, 治疗抵抗

Abstract:

Lumican is a member of the small leucine-rich proteoglycan family，which is involved in cell processes related to tumorigenesis and development，such as epithelial-mesenchymal transition，cell proliferation，migration，invasion and adhesion. The expression of Lumican in different tumors is positively or negatively correlated with tumor progression，and can be used as a reference for tumor prognosis and efficacy evaluation. Further study of the correlation and potential mechanism between Lumican and tumor therapy resistance can provide new ideas for predicting clinical therapeutic efficacy.

Key words: Neoplasms, Lumican, Therapy resistance

胡格, 夏凡, 吴雪芽, 王云, 徐秀理. Lumican与肿瘤治疗抵抗[J]. 国际肿瘤学杂志, 2023, 50(2): 87-90.

Hu Ge, Xia Fan, Wu Xueya, Wang Yun, Xu Xiuli. Lumican and tumor therapy resistance[J]. Journal of International Oncology, 2023, 50(2): 87-90.

参考文献 33

[1]	Matsushima N, Miyashita H, Kretsinger RH. Sequence features, structure, ligand interaction, and diseases in small leucine rich repeat proteoglycans[J]. J Cell Commun Signal, 2021, 15(4): 519-531. DOI: 10.1007/s12079-021-00616-4. doi: 10.1007/s12079-021-00616-4
[2]	Zappia J, Joiret M, Sanchez C, et al. From translation to protein degradation as mechanisms for regulating biological functions: a review on the SLRP family in skeletal tissues[J]. Biomolecules, 2020, 10(1): 80. DOI: 10.3390/biom10010080. doi: 10.3390/biom10010080
[3]	Matsushima N, Miyashita H, Tamaki S, et al. Shrinking of repeating unit length in leucine-rich repeats from double-stranded DNA viruses[J]. Arch Virol, 2021, 166(1): 43-64. DOI: 10.1007/s00705-020-04820-2. doi: 10.1007/s00705-020-04820-2 pmid: 33052487
[4]	Halari CD, Zheng M, Lala PK. Roles of two small leucine-rich proteoglycans decorin and biglycan in pregnancy and pregnancy-associated diseases[J]. Int J Mol Sci, 2021, 22(19): 10584. DOI: 10.3390/ijms221910584. doi: 10.3390/ijms221910584
[5]	Nizet P, Untereiner V, Sockalingum GD, et al. Assessment of ovarian tumor growth in wild-type and lumican-deficient mice: insights using infrared spectral imaging, histopathology, and immunohistochemistry[J]. Cancers (Basel), 2021, 13(23): 5950. DOI: 10.3390/cancers13235950. doi: 10.3390/cancers13235950
[6]	Liu C, Hu Y, Wang Z, et al. The downregulation of placental lumican promotes the progression of preeclampsia[J]. Reprod Sci, 2021, 28(11): 3147-3154. DOI: 10.1007/s43032-021-00660-w. doi: 10.1007/s43032-021-00660-w pmid: 34231169
[7]	Lee YS, Park SJ, Lee JY, et al. Benefits of lumican on human bone health: clinical evidence using bone marrow aspirates[J]. Korean J Intern Med, 2022, 37(4): 821-829. DOI: 10.3904/kjim.2022.015. doi: 10.3904/kjim.2022.015
[8]	Lee JY, Park SJ, Kim DA, et al. Muscle-derived lumican stimulates bone formation via integrin α2β1 and the downstream ERK signal[J]. Front Cell Dev Biol, 2020, 8:565826. DOI: 10.3389/fcell.2020.565826. doi: 10.3389/fcell.2020.565826
[9]	de Wit M, Carvalho B, Delis-van Diemen PM, et al. Lumican and versican protein expression are associated with colorectal adenoma-to-carcinoma progression[J]. PLoS One, 2017, 12(5): e0174768. DOI: 10.1371/journal.pone.0174768. doi: 10.1371/journal.pone.0174768
[10]	Appunni S, Anand V, Khandelwal M, et al. Altered expression of small leucine-rich proteoglycans (Decorin, Biglycan and Lumican): plausible diagnostic marker in urothelial carcinoma of bladder[J]. Tumour Biol, 2017, 39(5): 1010428317699112. DOI: 10.1177/1010428317699112. doi: 10.1177/1010428317699112
[11]	Appunni S, Rubens M, Ramamoorthy V, et al. Lumican, pro-tumorigenic or anti-tumorigenic: a conundrum[J]. Clin Chim Acta, 2021, 514: 1-7. DOI: 10.1016/j.cca.2020.12.011. doi: 10.1016/j.cca.2020.12.011 pmid: 33333043
[12]	Yamauchi N, Kanke Y, Saito K, et al. Stromal expression of cancer-associated fibroblast-related molecules, versican and lumican, is strongly associated with worse relapse-free and overall survival times in patients with esophageal squamous cell carcinoma[J]. Oncol Lett, 2021, 21(6): 445. DOI: 10.3892/ol.2021.12706. doi: 10.3892/ol.2021.12706 pmid: 33868483
[13]	Zang Y, Dong Q, Lu Y, et al. Lumican inhibits immune escape and carcinogenic pathways in colorectal adenocarcinoma[J]. Aging (Albany NY), 2021, 13(3): 4388-4408. DOI: 10.18632/aging.202401. doi: 10.18632/aging.202401
[14]	Lee JY, Kim DA, Kim EY, et al. Lumican inhibits osteoclastoge-nesis and bone resorption by suppressing Akt activity[J]. Int J Mol Sci, 2021, 22(9): 4717. DOI: 10.3390/ijms22094717. doi: 10.3390/ijms22094717
[15]	Klejewski A, Sterzyńska K, Wojtowicz K, et al. The significance of lumican expression in ovarian cancer drug-resistant cell lines[J]. Oncotarget, 2017, 8(43): 74466-74478. DOI: 10.18632/oncotarget.20169. doi: 10.18632/oncotarget.20169 pmid: 29088800
[16]	Li X, Truty MA, Kang Y, et al. Extracellular lumican inhibits pancreatic cancer cell growth and is associated with prolonged survival after surgery[J]. Clin Cancer Res, 2014, 20(24): 6529-6540. DOI: 10.1158/1078-0432.CCR-14-0970. doi: 10.1158/1078-0432.CCR-14-0970 pmid: 25336691
[17]	Li X, Roife D, Kang Y, et al. Extracellular lumican augments cytotoxicity of chemotherapy in pancreatic ductal adenocarcinoma cells via autophagy inhibition[J]. Oncogene, 2016, 35(37): 4881-4890. DOI: 10.1038/onc.2016.20. doi: 10.1038/onc.2016.20 pmid: 26876211
[18]	Li X, Kang Y, Roife D, et al. Prolonged exposure to extracellular lumican restrains pancreatic adenocarcinoma growth[J]. Oncogene, 2017, 36(38): 5432-5438. DOI: 10.1038/onc.2017.125. doi: 10.1038/onc.2017.125 pmid: 28534517
[19]	Sarcar B, Li X, Fleming JB. Hypoxia-induced autophagy degrades stromal lumican into tumor microenvironment of pancreatic ductal adenocarcinoma: a mini-review[J]. J Cancer Treatment Diagn, 2019, 3(1): 22-27. DOI: 10.29245/2578-2967/2019/1.1165. doi: 10.29245/2578-2967/2019/1.1165 pmid: 31406961
[20]	Kihira K, Chelakkot VS, Kainuma H, et al. Close interaction with bone marrow mesenchymal stromal cells induces the development of cancer stem cell-like immunophenotype in B cell precursor acute lymphoblastic leukemia cells[J]. Int J Hematol, 2020, 112(6): 795-806. DOI: 10.1007/s12185-020-02981-z. doi: 10.1007/s12185-020-02981-z
[21]	Yu Z, Liu L, Shu Q, et al. Leukemia stem cells promote chemoresistance by inducing downregulation of lumican in mesenchymal stem cells[J]. Oncol Lett, 2019, 18(4): 4317-4327. DOI: 10.3892/ol.2019.10767. doi: 10.3892/ol.2019.10767 pmid: 31579426
[22]	Li D, Lin TL, Lipe B, et al. A novel extracellular matrix-based leukemia model supports leukemia cells with stem cell-like characteristics[J]. Leuk Res, 2018, 72: 105-112. DOI: 10.1016/j.leukres.2018.08.012. doi: 10.1016/j.leukres.2018.08.012
[23]	张永丽, 张若佳, 范焕彩, 等. TXNDC5-Prx2途径对前列腺癌细胞耐药性的调控[J]. 国际肿瘤学杂志, 2021, 48(8): 473-478. DOI: 10.3760/cma.j.cn371439-20210324-00090. doi: 10.3760/cma.j.cn371439-20210324-00090
[24]	Wang JL, Wang Y, Ren GP. Identification of PTPRR and JAG1 as key genes in castration-resistant prostate cancer by integrated bioinformatics methods[J]. J Zhejiang Univ Sci B, 2020, 21(3): 246-255. DOI: 10.1631/jzus.B1900329. doi: 10.1631/jzus.B1900329
[25]	Athanasiou A, Tennstedt P, Wittig A, et al. A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology[J]. PLoS One, 2021, 16(11): e0259093. DOI: 10.1371/journal.pone.0259093. doi: 10.1371/journal.pone.0259093
[26]	Li Y, Su Z, Zhao W, et al. Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity[J]. Nat Cancer, 2020, 1(9): 882-893. DOI: 10.1038/s43018-020-0095-6. doi: 10.1038/s43018-020-0095-6
[27]	Momin N, Mehta NK, Bennett NR, et al. Anchoring of intratumo-rally administered cytokines to collagen safely potentiates systemic cancer immunotherapy[J]. Sci Transl Med, 2019, 11(498): eaaw2614. DOI: 10.1126/scitranslmed.aaw2614. doi: 10.1126/scitranslmed.aaw2614
[28]	Jeanne A, Untereiner V, Perreau C, et al. Lumican delays melanoma growth in mice and drives tumor molecular assembly as well as response to matrix-targeted TAX2 therapeutic peptide[J]. Sci Rep, 2017, 7(1): 7700. DOI: 10.1038/s41598-017-07043-9. doi: 10.1038/s41598-017-07043-9 pmid: 28794454
[29]	Brézillon S, Untereiner V, Mohamed HT, et al. Label-free infrared spectral histology of skin tissue part Ⅱ: impact of a lumican-derived peptide on melanoma growth[J]. Front Cell Dev Biol, 2020, 8: 377. DOI: 10.3389/fcell.2020.00377. doi: 10.3389/fcell.2020.00377 pmid: 32548117
[30]	Yamano Y, Uzawa K, Saito K, et al. Identification of cisplatin-resistance related genes in head and neck squamous cell carcinoma[J]. Int J Cancer, 2010, 126(2): 437-449. DOI: 10.1002/ijc.24704. doi: 10.1002/ijc.24704 pmid: 19569180
[31]	Farace C, Oliver JA, Melguizo C, et al. Microenvironmental modulation of decorin and lumican in temozolomide-resistant glioblastoma and neuroblastoma cancer stem-like cells[J]. PLoS One, 2015, 10(7): e0134111. DOI: 10.1371/journal.pone.0134111. doi: 10.1371/journal.pone.0134111
[32]	Yang CT, Li JM, Chu WK, et al. Downregulation of lumican acce-lerates lung cancer cell invasion through p120 catenin[J]. Cell Death Dis, 2018, 9(4): 414. DOI: 10.1038/s41419-017-0212-3. doi: 10.1038/s41419-017-0212-3
[33]	Chen X, Li X, Hu X, et al. LUM expression and its prognostic significance in gastric cancer[J]. Front Oncol, 2020, 10: 605. DOI: 10.3389/fonc.2020.00605. doi: 10.3389/fonc.2020.00605 pmid: 32500021

Lumican与肿瘤治疗抵抗

Lumican and tumor therapy resistance

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 33

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.